Tag Archives: failure

Rice, UH Startups Pitch: Bedsores, Erectile Dysfunction & More

Houston—Not all of the startups that participate in a pitch day are actually viable companies. But, usually, each startup founder will take a place on stage extolling the virtues of their technologies, the unaddressed markets, and ask for mentors, industry connections, and money. Samantha Lewis, co-founder of SpecMobile, took a different tack. The Rice University […]

Bio Roundup: Obamacare Persists, FDA Approves, Vertex Wows & More

The attempt to repeal and replace the Affordable Care Act took a major hit this week from Senate GOP holdouts who said the Better Care Reconciliation Act either tore down Medicaid too much or left too much of the ACA in place. A straight-up repeal, floated by Senate majority leader Mitch McConnell, was also shot […]

Posted in Boston blog main, Boulder/Denver blog main, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Wisconsin blog main, Wisconsin top stories | Tagged $910 million, 100 pioneer wellness, A.I., abalo, abaloparatide, ACA, adjuvant, Affordable Care Act, AI, Akcea Therapeutics, Alzheimer's, Amgen, Antibiotics, Approval, Artificial Intelligence, backbone, Better Care Reconciliation Act, Biotech, breast, cancer, Cerebral Adrenoleukodystrophy, Clarus, clinical studies, competitions, Cystic Fibrosis, director, donald J Trump, failure, FDA, Francis Collins, Fujifilm, fund, funding, Gilead Sciences, green light, healthcare, Hepatitis B, Hepatitis C, Herceptin, House of Representatives, Institute for Systems Biology, IPO, ISB, itching, IV, Lee Hood, Life Sciences, Mitch McConnell, Nektar Therapeutics, Neratinib, Nerlynx, NeuroVia, NIH, NKT-181, Novartis, Obamacare, omadacycline, opioid crisis, Osteoporosis, Paratek Pharmaceuticals, PDUFA, Phase 3, President, Puma Biotechnology, Radius Health, recess, romosozumab, Sanofi, Scott Gottlieb, Senate, sofobuvir, Study, Surgery, survery, Trastuzumab, Trevi Therapeutics, triple combination, Trumpcare, USAgainstAlzheimer's, velpatasvir, Venture Capital, Vertex Pharmaceuticals, Vosevi, voxilaprevir, White House | Comments Off

Merck Alzheimer Drug Is Latest To Fail In A Big Study

Another Alzheimer’s drug has failed a major test. Merck (NYSE: MRK) reported late Tuesday that its pill verubecestat was not helping people with significant Alzheimer’s symptoms. The drug maker announced that it halted its EPOCH study early because an oversight group said there was “virtually no chance of finding a positive clinical effect.” Verubecestat is […]

Posted in Boston blog main, Boston top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories | Tagged Alzheimer's, amyloid beta, APECS, Axovant Sciences, BACE, BACE for your FACE, BACE1, beta-amyloid, Biotech, clinical studies, Eli Lilly, EPOCH, failure, George Vradenburg, intepirdine, ISI Evercore, Life Sciences, Mark Schoenebaum, Merck, solanezumab, Trials, USAgainstAlzh, USAgainstAlzheimer's, verubecestat | Comments Off

Texas Roundup: HTC, Indigo, DEC, Rakesh Agrawal, Piko, & Top of 2016

Let’s catch up with the latest innovation news from Texas. —The Houston Technology Center has tapped Lori Vetters, a longtime commercial banker and civic leader, to become its next CEO. Vetters takes over the 17-year-old incubator from Walter Ulrich, a business consultant who led the center for nearly a decade. During that time, the innovation […]

Posted in National blog main, National top stories, Texas, Texas blog main, Texas top stories | Tagged AgTech, angel investing, Artificial Intelligence, Atari, austin, Dallas, Dallas Entrepreneur Center, Dallas-Fort Worth Urban League Young Professionals, EdTech, El Paso, El Paso Times, failure, Five Questions For, Frogger, Gaming, Hidden Figures, Hispanics, Houston, Houston Technology Center, human computers, Indigo, Las Vegas, Liver Disease, Lori Vetters, Lyft, Margot Lee Shetterly, Mediatech, Michelle Williams, nasa, Nintento, OfferCraft, Pac-Man, Piko Interactive, Rakesh Agrawal, Ride Sharing, San Antonio, Sego, SnapStream, Software, Southern Dallas Entrepreneur Network, Space, Super Noah's Ark 3D, Tech, Trey Bowles, Uber, Venture Capital, Walter Ulrich, Xconomy Bookclub | Comments Off

Beyond Success: Failure’s Importance in Building Viable Startups

Houston—Entrepreneurs are a mobile bunch, quickly moving from one startup to another as opportunities play themselves out and others emerge. So in speaking to Houston entrepreneur Rakshak Talwar, I was struck by his answer to my question about what he’s doing with a new artificial intelligence startup he’s joined. “I can show them what not […]

Posted in National blog main, National top stories, Texas, Texas blog main, Texas top stories | Tagged accelerators, artificial intellience, cleantech, Dallas, Demo days, failure, Gabriella Draney Zielke, Gauntlet, Houston, Intermountain Health, Investors, Kerri Smith, Marketing Interface, medical devices, Melanie Jones, OwlSpark, Rakshak Talwar, Raptorbird, Rice University, Salt Lake City, Seed Accelerator Rankings Project, startups, Surge, Tech, Tech Wildcatters, Texas Medical Center, TMCx, Todd Dunn, University of Houston, Venture Capital, Yael Hochberg | Comments Off

Five Questions For … Nick Kennedy, Founder of Dallas-Based Rise

Dallas — Texas is a far-flung state with metro-city populations that are about 200 miles away from each other. Because of that, tech innovation circles tend to largely stay amongst themselves, with the occasional meetup at South By Southwest Interactive in Austin. As a way for people around the state to get to know each […]

Posted in National blog main, National top stories, Texas, Texas blog main, Texas top stories | Tagged austin, Aviation, baseball, Calvin Howe, colorado, Dallas, Entrepreneur, exits, failure, Five Questions For, Hampton Inn, Harding University, Houston, innovation, Ironman, Los Angeles, Los Angeles Angels, Los Angeles Dodgers, Mike Scioscia, Nick Kennedy, people, Rise, San Antonio, San Diego Padres, Searcy AR, Software, startups, triathalon | Comments Off

West Coast Bio Roundup: Google/Insel, SeaGen, Avalon, Alector & More

It’s not specific to the West Coast, but anyone who needs to catch up on the week’s events should read the British Medical Journal’s re-analysis of a long-criticized study, dubbed Study 329, of the antidepressant paroxetine (Paxil) in an adolescent population. It took place in the 1990s, run by SmithKline Beecham (now GlaxoSmithKline). Paroxetine was […]

Posted in National blog main, National top stories, San Diego blog main, San Diego top stories, San Francisco, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories | Tagged Alector, Alliance Bernstein, Amgen, Arnon Rosenthal, Avalon Ventures, Biotech, Bispecific Antibodies, blinatumumab, Brett Hall, British Medical Journal, cancer immunotherapy, Capsule Technologie, Celgene, Cholesterol, Dezima Pharma, Ebola, failure, follow on financing, FOPO, Gary Kurtzman, Google Life Sciences, LeafBio, Life Sciences, Mapp Biopharmaceutical, Molecular Response, MRL Ventures, NASH, new fund, nonalcoholic steatohepatitis, Nurix, Omada Health, Paroxetine, Paxil, Prevent, Protein Homeostasis, Psoriasis, Qualcomm Life, Raptor Pharmaceutical, re-analysis, Repatha, Rob Califf, Seattle Genetics, SmithKline Beecham, Study 329, Thomas Insel, Tom Insel, torceptrapib, Trial, University of California San Francisco, University of Chicago, University of Toronto, VC, VentriGel, Ventrix, Venture Capital, Xencor, Xenoport | Comments Off

Failure:Lab Offers Empowerment Through Personal Tales of Woe

Failure: We’ve all experienced it, and, in the startup world, failure is often seen as a necessary step on the path to success. But if it’s such a universal experience, why are we so reluctant to talk about it? Wouldn’t we all feel a little better if we knew our friends and neighbors struggle just […]

Posted in Detroit, Detroit blog main, Detroit top stories, National blog main | Tagged Austin Dean, Entrepreneurship, events, Faillure:Lab, failure, GR Current, innovation, Internet, startups | 1 Comment

West Coast Biotech Roundup: Gilead/AbbVie, Juno, Auspex, Bina & More

It was a very good year for the Bay Area’s Gilead Sciences (NASDAQ: GILD), which saw its new hepatitis C treatments— sofosbuvir (Sovaldi) and Harvoni (a combination of sofosbuvir and ledipasvir)—make big inroads and help cure patients, even as the price tag of the drugs raised ire. Hackles were up not just among longtime industry watchdogs like […]

Posted in National blog main, National top stories, San Diego blog main, San Diego top stories, San Francisco, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories | Tagged AbbVie, AMG 319, AMG319, Amgen, Annexon Bioscience, Auspex Pharmaceuticals, Avalon Ventures, Bellicum Pharmaceuticals, Bina Technologies, Biotech, Cancer Research UK, cardiac catheter, Celgene, Dartmouth College, diabetes, Elan, Express Scripts, failture, failure, First Opinion, Flexus Biosciences, Floyd Romesberg, formulary, gantenerumab, Genentech, Gilead Sciences, Halozyme Therapeutics, Harvard Business Review, Harvoni, Henry Waxman, Hepatitis C, Huntington's Disease, IPO, Janssen Biotech, Janssen Pharmaceuticals, John Martin, Juno Therapeutics, Kleiner Perkins Caufield & Byers, ledipasvir, Life Sciences, NantWorks, Novartis Venture Funds, Novo Nordisk, Patrick Soon-Shiong, PI3K inhibitors, Polaris Partners, Robert Ludlum, Roche, Roundup, Royal Philips, Science Magazine, Sevion, sofosbuvir, Sophiris Bio, Sorrento Therapeutics, Sovaldi, Steve Miller, Synthorx, The Column Group, The Scripps Research Institute, The Viekira Pact, Tuck School of Business at Dartmouth, Tysabri, Ultrasound, Viekira Pak, Volcano Corp, Xencor | Comments Off← Older posts Newer posts →